Skip to main content

Cardiol Therapeutics Inc.

CRDL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001702123

No open-market purchases or sales by Cardiol Therapeutics Inc. insiders were filed in the last 90 days; 52 institutions reported holding it in 13F filings for Q2 2026, worth $31.3M in total; no superinvestor holds it.

Q1 2026 vs. Q4 2025

How the institutions holding Cardiol Therapeutics Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026All holders in Q4 2025

13F holders of CRDL: Q4 2025 compared with Q1 2026
MeasureQ4 2025Q1 2026Change
Holders4147+6
Shares9.10M27.9M+18.8M (+206.3%)
Value$8.69M$37.6M+$28.9M (+332.6%)

New holders (15)

Institutions that held Cardiol Therapeutics Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to CRDL in Q1 2026
InstitutionSharesValue% of portfolio
Ikarian Capital, LLC2,725,000$3.68M0.53%
Citadel Advisors LLC819,904$1.11M0.00%
Boothbay Fund Management, LLC794,881$1.07M0.03%
Renaissance Technologies LLC229,806$310.2K0.00%
Quadrature Capital Ltd47,887$64.6K0.00%
JPMorgan Chase & Co48,077$58.7K0.00%
Kovack Advisors, Inc.30,000$42.0K0.00%
Virtu Financial LLC23,917$32.0K0.00%
Scientech Research LLC15,178$20.5K0.02%
Boomfish Wealth Group, LLC14,423$19.5K0.01%
Eaton Financial Holdings Company, LLC14,000$18.9K0.01%
BNP Paribas Arbitrage, SA10,000$13.5K0.00%
Advisory Services Network, LLC10,000$13.5K0.00%
Baader Bank INC15,932$10.2K0.00%
Barclays PLC200$2700.00%

Sold out (9)

Institutions that held Cardiol Therapeutics Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of CRDL in Q1 2026
InstitutionShares, Q4 2025Value, Q4 2025
AdvisorShares Investments LLC597,977$570.4K
Bank of America Corp367,453$350.2K
Marshall Wace, LLP151,517$143.9K
Simplex Trading, LLC32,197$30.7K
Two Sigma Advisers, LP19,100$18.2K
Wealth Enhancement Advisory Services, LLC16,552$16.6K
GWM Advisors LLC5,000$4.77K
Disciplined Equity Management, Inc.500$605
Optima Capital LLC28$27